Interní Med. 2012; 14(6-7): 253-256

Alternatives for the phamacotherapy of hypertension in patients with metabolic syndrome

MUDr.Zuzana Stránská
3. interní klinika VFN a 1. LF UK v Praze

Prevalence of metabolic syndrome (MS) is rising as a consequence of obesity epidemic. The components of MS are related to each other

and together with hypertension represent a hight risk for cardiovascular diseases. Antihypertensive drugs with favorable metabolic

efect should be chosen for treatment of hypertension in MS. Treatment of hypertension in patients with MS follows the same rules as

in diabetics. Pharmacotherapy is indicated when blood pressure values reach ≥ 140/90 mmHg. In diabetics, the exact target for blood

pressure has not been determined yet. A combination therapy is usually necessary to achieve a decrease of blood pressure under 140/90

mmHg in patients with diabetes and ACE-I/sartans medication should be prefered. Finally, there is a prognostic relevance to involve the

rest components of MS pharmacologically.

Keywords: hypertension, metabolic syndrome, type 2 diabetes, obesity

Published: July 31, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Stránská Z. Alternatives for the phamacotherapy of hypertension in patients with metabolic syndrome. Interní Med. 2012;14(6-7):253-256.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lee HY, Oh BH. Aging and arterial stiffness. Circ J. 2010 Nov; 74(11): 2257-2262. Go to original source... Go to PubMed...
    2. Pinto E. Blood pressure and ageing. Postgrad Med J. 2007 Feb; 83(976): 109-114. Go to original source... Go to PubMed...
    3. Izumi Y, Matsumoto K, Ozawa Y, Kasamaki Y, Shinndo A, Ohta M, et al. Effect of age at menopause on blood pressure in postmenopausal women. Am J Hypertens. 2007 Oct; 20(10): 1045-1050. Go to original source... Go to PubMed...
    4. Mancia G, Bombelli M, Facchetti R, Casati A, Ronchi I, Quarti-Trevano F, et al. Impact of different definitions of the metabolic syndrome on the prevalence of organ damage, cardiometabolic risk and cardiovascular events. J Hypertens. May; 28(5): 999-1006. Go to original source... Go to PubMed...
    5. da Silva AA, do Carmo J, Dubinion J, Hall JE. The role of the sympathetic nervous system in obesity-related hypertension. Curr Hypertens Rep. 2009 Jun; 11(3): 206-211. Go to original source... Go to PubMed...
    6. Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G. Mechanisms of obesity-induced hypertension. Hypertens Res. 2010 May; 33(5): 386-393. Go to original source... Go to PubMed...
    7. Coatmellec-Taglioni G, Ribiere C. Factors that influence the risk of hypertension in obese individuals. Curr Opin Nephrol Hypertens. 2003 May; 12(3): 305-308. Go to original source... Go to PubMed...
    8. Wang ZV, Scherer PE. Adiponectin, cardiovascular function, and hypertension. Hypertension. 2008 Jan; 51(1): 8-14. Go to original source... Go to PubMed...
    9. Xu X, Jhun BS, Ha CH, Jin ZG. Molecular mechanisms of ghrelin-mediated endothelial nitric oxide synthase activation. Endocrinology. 2008 Aug; 149(8): 4183-4192. Go to original source... Go to PubMed...
    10. Svačina Š. Hypertenze při obezitě a diabetu. Triton 2007.
    11. Widimsky J, Jr. [Treatment of hypertension in metabolic syndrome]. Vnitr Lek. 2009 Jul-Aug; 55(7-8): 631-635. Go to PubMed...
    12. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998 Sep 12; 317(7160): 703-713.
    13. Cífková R. Farmakoterapie arteriální hypertenze u pacientů s diabetes mellitus 2. typu. Remedia 2012; 22: 14-20.
    14. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009 Nov; 27(11): 2121-2158. Go to original source... Go to PubMed...
    15. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec; 42(6): 1206-1252. Go to original source... Go to PubMed...
    16. Zanchetti A, Mancia G, Black HR, Oparil S, Waeber B, Schmieder RE, et al. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens. 2009 Apr; 27(4): 673-679. Go to original source... Go to PubMed...
    17. Fagard R. Reappraisal of the European guidelines on hypertension management: the European Society of Hypertension Task Force document: a short review. Pol Arch Med Wewn. 2010; 120(1-2): 31-35. Go to original source... Go to PubMed...
    18. Widimsky J, Jr., Cifkova R, Spinar J, Filipovsky J, Grundmann M, Horky K, et al. [Recommended diagnostic and therapeutic approach in arterial hypertension-2007 version. Recommendations of the Czech Hypertension Society]. Vnitr Lek. 2008 Jan; 54(1): 101-110, 112, 114-118. Go to PubMed...
    19. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006 Jan; 24(1): 3-10. Go to original source... Go to PubMed...
    20. Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006 Dec; 29(12): 2592-2597. Go to original source... Go to PubMed...
    21. Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol. 2006 Apr; 17(4 Suppl 2): S90-97. Go to original source... Go to PubMed...
    22. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004 Nov 4; 351(19): 1941-1951. Go to original source... Go to PubMed...
    23. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23; 359(9311): 1004-1010. Go to original source... Go to PubMed...
    24. Redon J, Cifkova R, Narkiewicz K. Hypertension in the metabolic syndrome: summary of the new position statement of the European Society of Hypertension. Pol Arch Med Wewn. 2009 Apr; 119(4): 255-260. Go to original source... Go to PubMed...
    25. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007 Sep 8; 370(9590): 829-840. Go to original source... Go to PubMed...
    26. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996 Dec 18; 276(23): 1886-1892. Go to original source...
    27. Lithell H. Hypertension and hyperlipidemia. A review. Am J Hypertens. 1993 Nov; 6(11 Pt 2): 303S-308S. Go to original source... Go to PubMed...
    28. Sharma AM, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J Hum Hypertens. 2004 Sep; 18(9): 669-675. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.